Related Experiment Video

Updated: Sep 8, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

840

Would Tracking Coagulation Together with Inflamation Markers be a Prospect for COVID-19 Disease Prognosis?

Alpay Medetalibeyoglu, Murat Kaytaz, Naci Senkal

    Clinical Laboratory
    |June 15, 2022
    PubMed

    Insights

    Coagulation tests like prothrombin time (PT) and D-dimer can predict COVID-19 severity. Monitoring these hemostatic markers aids in prognosis and timely treatment decisions for SARS-CoV-2 patients.

    Area of Science:

    • Hematology
    • Infectious Diseases
    • Critical Care Medicine

    Background:

    • COVID-19 (SARS-CoV-2) presents a significant global health challenge.
    • Understanding disease progression and prognostic markers is crucial for patient management.
    • Coagulation and inflammatory markers are implicated in severe COVID-19 outcomes.

    Purpose of the Study:

    • To evaluate the prognostic value of hemostatic tests (PT, aPTT, fibrinogen, D-dimer, antithrombin III) in COVID-19.
    • To assess the relationship between coagulation parameters and disease severity (mild, moderate, severe).
    • To explore the association between coagulation markers and inflammatory markers (CRP, procalcitonin, IL-6).

    Main Methods:

    • Prospective study of 604 COVID-19 patients admitted to the Emergency Department.
    • Coagulation tests and inflammatory markers were measured serially from admission to day 10.
    • Statistical analysis compared marker levels across different disease severity groups.

    Main Results:

    • Severe COVID-19 cases showed significantly different PT and PT activity compared to mild cases.
    • Activated partial thromboplastin time (aPTT) and D-dimer levels were significantly higher in severe cases.
    • Fibrinogen levels were lowest in mild cases and highest in severe cases, indicating a strong correlation with disease severity.

    Conclusions:

    • Hemostatic parameters are vital for monitoring COVID-19 patients.
    • Measuring and monitoring coagulation tests at admission aids in determining disease severity and prognosis.
    • Timely assessment of coagulation markers supports appropriate treatment selection and application.
    Abstract

    More Related Videos

    Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

    Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

    Published on: January 28, 2020

    5.4K
    Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia07:25

    Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

    Published on: September 22, 2020

    3.5K

    Related Concept Videos

    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

    Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
    These markers indicate stress or strain on the heart muscle:
    Natriuretic Peptides (BNP)
    Cardiac myocytes produce these hormones in response to ventricular stretching...
    213
    Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

    Blood Studies for Cardiovascular System I: Cardiac Biomarkers

    Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
    The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
    Troponins
    Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
    330
    Coagulation01:09

    Coagulation

    The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
    During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
    7.4K
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    887
    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    22
    Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

    Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

    The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
    31